The University of Chicago Header Logo

Connection

Stephen Hanauer to Inflammatory Bowel Diseases

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Inflammatory Bowel Diseases.
Stephen Hanauer
Connection Strength
16.755
Inflammatory Bowel Diseases
  1. The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2023 Jul-Dec; 19(9):1075-1089.
    View in: PubMed
    Score: 0.579
  2. Hospitalization Experiences and Post-traumatic Stress in Inflammatory Bowel Disease: Opportunities for Change. Inflamm Bowel Dis. 2023 05 02; 29(5):675-683.
    View in: PubMed
    Score: 0.576
  3. COVID-19 and Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2023 03; 52(1):103-113.
    View in: PubMed
    Score: 0.557
  4. Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes. Inflamm Bowel Dis. 2022 05 04; 28(5):710-719.
    View in: PubMed
    Score: 0.538
  5. Review article: drug-induced small bowel injury. Aliment Pharmacol Ther. 2021 12; 54(11-12):1370-1388.
    View in: PubMed
    Score: 0.518
  6. Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape. Curr Gastroenterol Rep. 2021 Aug 02; 23(9):16.
    View in: PubMed
    Score: 0.511
  7. Executive Summary of 'Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States'. Am J Gastroenterol. 2020 09; 115(9):1362-1366.
    View in: PubMed
    Score: 0.479
  8. Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. Inflamm Bowel Dis. 2020 08 20; 26(9):1291-1305.
    View in: PubMed
    Score: 0.478
  9. Drug-Induced Colitis. Clin Gastroenterol Hepatol. 2021 09; 19(9):1759-1779.
    View in: PubMed
    Score: 0.468
  10. Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2019 08 20; 25(9):1577-1585.
    View in: PubMed
    Score: 0.446
  11. Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology. Inflamm Bowel Dis. 2019 08 20; 25(9):e114.
    View in: PubMed
    Score: 0.446
  12. Perspectives of Clinicians in the United States and Europe on Monitoring Levels of Biologic Agents in Patients Receiving Biologic Therapies for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1718-1723.
    View in: PubMed
    Score: 0.441
  13. More Than a Tumor Marker…A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 06 18; 25(7):1271-1276.
    View in: PubMed
    Score: 0.441
  14. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf. 2015; 14(12):1915-34.
    View in: PubMed
    Score: 0.343
  15. Reply: To PMID 25311382. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2384-5.
    View in: PubMed
    Score: 0.336
  16. Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015 Mar; 13(3):548-51.
    View in: PubMed
    Score: 0.319
  17. Comparing guidelines for the treatment of inflammatory bowel disease. Dig Dis. 2013; 31(3-4):360-2.
    View in: PubMed
    Score: 0.299
  18. Disease modification in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Sep; 10(9):954-5.
    View in: PubMed
    Score: 0.271
  19. Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5.
    View in: PubMed
    Score: 0.269
  20. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr; 106(4):685-98.
    View in: PubMed
    Score: 0.249
  21. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
    View in: PubMed
    Score: 0.244
  22. Inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul; 6(4):499-500.
    View in: PubMed
    Score: 0.237
  23. Devolving therapeutic pyramids. Nat Rev Gastroenterol Hepatol. 2010 Mar; 7(3):119-20.
    View in: PubMed
    Score: 0.231
  24. The expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010 Feb; 7(2):63-4.
    View in: PubMed
    Score: 0.230
  25. Optimizing conventional therapies for inflammatory bowel disease. Curr Gastroenterol Rep. 2009 Dec; 11(6):496-503.
    View in: PubMed
    Score: 0.227
  26. Don't miss the forest for the trees. Inflamm Bowel Dis. 2009 Sep; 15(9):1397-8.
    View in: PubMed
    Score: 0.224
  27. Exploring the controversial themes of IBD. Inflamm Bowel Dis. 2009 Sep; 15 Suppl 1:S1-10.
    View in: PubMed
    Score: 0.224
  28. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009 Jun; 3(3):235-48.
    View in: PubMed
    Score: 0.220
  29. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
    View in: PubMed
    Score: 0.220
  30. Semantics. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb; 5(2):59.
    View in: PubMed
    Score: 0.200
  31. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
    View in: PubMed
    Score: 0.200
  32. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(3):159-68.
    View in: PubMed
    Score: 0.199
  33. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3.
    View in: PubMed
    Score: 0.195
  34. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):209-14.
    View in: PubMed
    Score: 0.187
  35. The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S1-2.
    View in: PubMed
    Score: 0.186
  36. Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S3-10.
    View in: PubMed
    Score: 0.186
  37. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73.
    View in: PubMed
    Score: 0.185
  38. The 'tipping point' applied. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):59.
    View in: PubMed
    Score: 0.174
  39. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006 Jan; 12 Suppl 1:S3-9.
    View in: PubMed
    Score: 0.173
  40. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005 Sep 01; 22(5):441-6.
    View in: PubMed
    Score: 0.169
  41. Assessment, prevention and treatment of osteoporosis in inflammatory bowel disease patients: a bone of contention. Nat Clin Pract Gastroenterol Hepatol. 2005 May; 2(5):199.
    View in: PubMed
    Score: 0.166
  42. COLAL-PRED Alizyme. Curr Opin Investig Drugs. 2004 Nov; 5(11):1192-7.
    View in: PubMed
    Score: 0.160
  43. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S18-23.
    View in: PubMed
    Score: 0.150
  44. Post-traumatic stress disorder symptoms are frequent among inflammatory bowel disease patients of South Asian descent-A case-control study. Indian J Gastroenterol. 2024 Feb; 43(1):244-253.
    View in: PubMed
    Score: 0.149
  45. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14.
    View in: PubMed
    Score: 0.145
  46. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
    View in: PubMed
    Score: 0.141
  47. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2023 04; 21(4):878-890.
    View in: PubMed
    Score: 0.139
  48. Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy. Inflamm Bowel Dis. 2022 10 03; 28(10):1603-1606.
    View in: PubMed
    Score: 0.138
  49. New steroids for IBD: progress report. Gut. 2002 Aug; 51(2):182-3.
    View in: PubMed
    Score: 0.137
  50. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
    View in: PubMed
    Score: 0.136
  51. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
    View in: PubMed
    Score: 0.131
  52. Patient Perspectives on Medical Trauma Related to Inflammatory Bowel Disease. J Clin Psychol Med Settings. 2022 09; 29(3):596-607.
    View in: PubMed
    Score: 0.127
  53. Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med. 2001; 52:299-318.
    View in: PubMed
    Score: 0.123
  54. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000 Nov; 23(5):429-48.
    View in: PubMed
    Score: 0.121
  55. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62.
    View in: PubMed
    Score: 0.119
  56. Evolutionary biologic therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 1999 Dec; 1(6):467-9.
    View in: PubMed
    Score: 0.114
  57. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):297-321.
    View in: PubMed
    Score: 0.110
  58. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol. 2019 05; 75(5):846-852.
    View in: PubMed
    Score: 0.106
  59. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018 Apr; 47(8):1092-1102.
    View in: PubMed
    Score: 0.101
  60. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202.
    View in: PubMed
    Score: 0.100
  61. How do I treat erythema nodosum, aphthous ulcerations, and pyoderma gangrenosum? Inflamm Bowel Dis. 1998 Feb; 4(1):70; discussion 73.
    View in: PubMed
    Score: 0.100
  62. The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure. Inflamm Bowel Dis. 2017 04; 23(4):561-569.
    View in: PubMed
    Score: 0.095
  63. Vitamin D Levels and Outcomes in Inflammatory Bowel Disease-Which is the Chicken and Which is the Egg? Clin Gastroenterol Hepatol. 2017 02; 15(2):247-248.
    View in: PubMed
    Score: 0.092
  64. Integrating Adolescents and Young Adults into Adult-Centered Care for IBD. Curr Gastroenterol Rep. 2016 May; 18(5):21.
    View in: PubMed
    Score: 0.089
  65. New therapeutic approaches. Gastroenterol Clin North Am. 1995 Sep; 24(3):523-40.
    View in: PubMed
    Score: 0.085
  66. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38.
    View in: PubMed
    Score: 0.085
  67. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17.
    View in: PubMed
    Score: 0.083
  68. Medical therapy of inflammatory bowel disease. Med Clin North Am. 1994 Nov; 78(6):1413-26.
    View in: PubMed
    Score: 0.080
  69. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35.
    View in: PubMed
    Score: 0.077
  70. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013 Sep; 123(9):3983-96.
    View in: PubMed
    Score: 0.074
  71. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8.
    View in: PubMed
    Score: 0.071
  72. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis. 2012 Feb; 6 Suppl 2:S260-7.
    View in: PubMed
    Score: 0.066
  73. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991 May-Jun; 6(3):192-219.
    View in: PubMed
    Score: 0.063
  74. Aminosalicylates: old and new. Mt Sinai J Med. 1990 Oct; 57(5):283-7.
    View in: PubMed
    Score: 0.060
  75. Inflammatory bowel disease revisited: newer drugs. Scand J Gastroenterol Suppl. 1990; 175:97-106.
    View in: PubMed
    Score: 0.057
  76. A poor view from specialty silos. Nat Rev Gastroenterol Hepatol. 2010 Jan; 7(1):1-2.
    View in: PubMed
    Score: 0.057
  77. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39.
    View in: PubMed
    Score: 0.048
  78. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8.
    View in: PubMed
    Score: 0.043
  79. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jul; 2(7):308-15.
    View in: PubMed
    Score: 0.042
  80. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(2):66-85.
    View in: PubMed
    Score: 0.038
  81. Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet. 2002 Oct 01; 11(21):2599-606.
    View in: PubMed
    Score: 0.035
  82. Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum Mol Genet. 2000 May 22; 9(9):1425-32.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.